-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2030 Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Program: Oral and Poster Abstracts
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Lymphoid Malignancies, Minimal Residual Disease
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Nikhil C Munshi, MD, PhD1, Bruno Paiva2*, Thomas Martin, MD3, Saad Usmani, MD4, Yi Lin, MD, PhD5, Jordan M Schecter6, Carolyn C Jackson6*, Deepu Madduri, MD6*, Enrique Zudaire7, Tzu-min Yeh6*, J Blake Bartlett8, Lida Pacaud9*, Muhammad Akram9*, Dong Geng9*, Sundar Jagannath10, Adam D Cohen, MD11 and Jesús San-Miguel, MD, PhD2

1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, and VA Boston Healthcare System, West Roxbury, MA
2University of Navarra, Pamplona, Spain
3UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
4Memorial Sloan Kettering Cancer Center, New York, NY
5Division of Hematology, Mayo Clinic, Rochester, MN
6Janssen Research & Development, Raritan, NJ
7Janssen Research & Development, Spring House, PA
8Janssen Research & Development, Bridgewater, NJ
9Legend Biotech USA, Piscataway, NJ
10Mount Sinai Medical Center, New York, NY
11Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Introduction: Cilta-cel is a BCMA-targeting CAR T-cell therapy that was recently approved by the US FDA for the treatment of adult patients (pts) with relapsed/refractory multiple myeloma (RRMM) after ≥4 prior lines of therapy (LOT) including a proteasome inhibitor (PI), immunomodulatory drug (IMiD), and anti-CD38 monoclonal antibody. In the phase 1b/2 CARTITUDE-1 study, cilta-cel demonstrated deep and durable responses in heavily pretreated pts with RRMM. The ORR was 97.9%, and at a median follow-up of 28 months (mo) the DOR was not reached. Of the 97 pts, 61 were evaluable for minimal residual disease (MRD) negativity (clonoSEQ v2.0, Adaptive Biotechnologies), with 56 (91.8%) of these 61 pts achieving MRD negativity (10‑5) at any point. We sought to characterize the baseline and disease characteristics of pts with sustained MRD negativity (pts who continued to remain MRD negative ≥6 mo and ≥12 mo).

Methods: Eligible pts had MM and received ≥3 prior therapies or were refractory to a PI, and IMiD, and had received a PI, IMiD, and an anti-CD38 antibody. Pts received a single cilta-cel infusion (target dose 0.75x106 CAR+ viable T cells/kg) 5–7 days post lymphodepletion. MRD negativity was a secondary objective of the phase 2 part of CARTITUDE-1 and was assessed on bone marrow samples at baseline; day 28; and 6, 12, 18, and 24 mo using next-generation sequencing, regardless of disease status. An additional sample was collected and assessed at the time of suspected complete response and every 12 mo until progressive disease (PD) for pts who remained on the study. Evaluable samples passed calibration and quality control and included sufficient cells for evaluation at 10-5 testing threshold. Characteristics were analyzed in pts who had MRD negativity <6 mo, or sustained ≥6 mo and ≥12 mo. Pts who did not achieve MRD negativity at any time point were considered to be MRD positive. Landmark analyses were conducted at 6 and 12 mo to address immortal time bias.

Results: Of the 56 pts who achieved MRD negativity in CARTITUDE-1, 50 had at least 6 mo follow up without progression after initial MRD-negativity and 44 had at least 12 mo follow up without progression after initial MRD-negativity. MRD negativity was sustained for ≥6 mo in 68% (34 of 50 with at least 6 mo follow-up without progression after initial MRD-negativity) and ≥12 mo in 55% (24 of 44 with at least 12 mo follow-up without progression after initial MRD‑negativity; all 6 pts evaluable for sustained MRD at ≥6 mo but not ≥12 mo had PD). Pts with sustained MRD negativity (≥6 mo, and ≥12 mo) had longer progression free survival (PFS; Figure 1A) compared with pts who did not (MRD negative <6 mo; consistent with results from landmark analyses). Key pt and disease characteristics in these different groups (Figure 1B), and potential associations with sustained MRD negativity were analyzed descriptively. Baseline extramedullary plasmacytomas were less common in pts with MRD sustained for ≥6 mo (8.8%, n=3/34) and ≥12 mo (4.2%, n=1/24) compared with pts who had MRD negativity <6 mo (18.2%, n=4/22). Pts with sustained MRD negativity also had trends toward longer median time since diagnosis (5.9 y and 7.0 y for pts with MRD negativity sustained ≥6 and ≥12 mo, respectively versus 4.8 y for those with MRD negativity <6 mo). Other baseline characteristics, including presence of high-risk cytogenetics, ECOG performance status, ISS stage, number of prior LOT, penta-drug refractoriness, and refractoriness to last LOT did not differ across MRD subgroups, and were similar to the overall CARTITUDE-1 population.

Conclusions: Based on our descriptive analysis, pts receiving cilta-cel achieved MRD negativity irrespective of their high-risk cytogenetics and ISS status, number of prior LOT and penta-drug refractoriness. While MRD negativity alone (<6 mo group) did not appear to provide PFS benefit when compared to MRD positive pts, the small number of pts in the MRD positive group prevents comparisons with those who achieved MRD negativity. Presence of extramedullary plasmacytoma at baseline, and time since diagnosis might be factors that impact achievement of sustained MRD negativity. These data suggest that while cilta-cel is effective for a broad range of pts, specific pt and disease characteristics may be associated with sustained MRD negativity and better long-term outcomes.

Figure 1: (A) Progression Free Survival (B) Pt Demographics and Disease Characteristics

Disclosures: Munshi: Amgen: Consultancy; Janssen: Consultancy; Bristol-Myers Squibb: Consultancy; Takeda Oncology: Consultancy; GSK: Consultancy; Oncopep: Consultancy, Current equity holder in publicly-traded company, Other: scientific founder, Patents & Royalties; Novartis: Consultancy; Pfizer: Consultancy; Abbvie: Consultancy; Karyopharm: Consultancy; Adaptive Biotechnology: Consultancy; Celgene: Consultancy; Legend: Consultancy. Paiva: GSK: Honoraria, Research Funding; Amgen: Honoraria; Takeda: Honoraria, Research Funding; Adaptive: Honoraria; EngMab: Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Roche Glycart AG: Honoraria, Research Funding; Gliead: Honoraria; Oncopeptides: Honoraria. Martin: GlaxoSmithKline and Legend Biotech: Consultancy; Legend Biotech: Consultancy; Amgen, Johnson & Johnson / Janssen, Sanofi, and Seattle Genetics: Research Funding. Usmani: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen Pharmaceuticals, Merck, Pharmacyclics, Sanofi, Seagen Inc., formerly Seattle Genetics, Inc., SkylineDX, Takeda: Consultancy; AbbVie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen Pharmaceuticals, Oncopeptides, Sanofi, Seagen Inc., formerly Seattle Genetics, Inc., Secura Bio, Inc., SkylineDX, Takeda, TeneoBio , Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen: Research Funding; Amgen, BMS, Janssen Pharmaceuticals, Sanofi: Speakers Bureau. Lin: Bluebird Bio: Consultancy, Research Funding; Legend: Consultancy; Gamida Cell: Consultancy; Celgene: Consultancy, Research Funding; Juno: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Novartis: Consultancy; Takeda: Research Funding; Merck: Research Funding; Vineti: Consultancy; Sorrento: Consultancy. Schecter: Janssen: Current Employment, Current holder of stock options in a privately-held company. Jackson: Janssen R&D: Current Employment. Madduri: BMS, Takeda, GSK, Kinevant, Legend, Sanofi, Celgene: Consultancy; Amgen, Allogene, BMS, Celgene: Research Funding; Janssen: Current Employment. Zudaire: Janssen R&D, Johnson and Johnson: Current Employment. Yeh: Janssen R&D, LLC: Current Employment. Bartlett: Janssen: Current Employment, Current equity holder in publicly-traded company. Pacaud: Legend Biotech USA: Current Employment. Geng: Legend Biotech USA: Current Employment. Jagannath: Janssen Pharmaceuticals: Consultancy; BMS: Consultancy; Legend Biotech: Consultancy; Sanofi: Consultancy; Karyopharm: Consultancy; Takeda: Consultancy. Cohen: Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Ichnos, Janssen Oncology, Oncopeptides, Pfizer, Seattle Genetics, Genentech/Roche, AstraZeneca, and Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline and Novartis: Research Funding; Novartis: Patents & Royalties: CAR T-cells and biomarkers of cytokine-release syndrome. San-Miguel: Abbvie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Takeda, Regeneron, Roche, Sanofi, and SecuraBio: Consultancy, Other: Advisory Board.

*signifies non-member of ASH